SynthesisFrontiers in endocrinology2025
The association of triglyceride-glucose index with cancer incidence and mortality: a systematic review and meta-analysis of cohort studies.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comprehensive evaluation of the prevalent insulin resistance indices for pan-cancer incidence and mortality prediction.Tropical medicine and health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study seeks to summarize the relationship between the triglyceride-glucose (TyG) index, a novel and reliable surrogate indicator of insulin resistance, and cancer-associated outcomes through meta-analysis. Methods: A thorough search was performed in PubMed, Embase, and Web of Science to identify cohort studies examining the relationship between the TyG index and cancer-associated outcomes. Adjusted hazard ratios (HR) with their 95% confidence intervals (CI) were pooled through random-effect meta-analyses. HRs were calculated using the TyG index as a continuous variable and as a categorial variable. Results: Twenty-two studies were included in this systematic review. Meta-analysis of seven studies comparing the highest TyG group to the lowest TyG group showed a significantly increased risk of cancer in the former group (HR = 1.16, 95% CI 1.08-1.25). The same result was found when pooling the HRs from studies analyzing the TyG index as a continuous variable (HR = 1.08, 95% CI 1.05-1.11). The pooled results of two studies identified a significant association between the TyG index and cancer-related mortality among cancer-diagnosed people (HR = 1.21, 95% CI 1.06-1.39). Additionally, studies observed no association between the TyG index and cancer-related mortality among cancer-free people (HR = 1.02, 95% CI 0.93-1.12), as well as all-cause mortality in cancer patients (HR = 0.98, 95% CI 0.58-1.64). Conclusion: Our findings indicate that a higher TyG index is associated with an increased risk of cancer, but shows no significant overall association with cancer prognosis. Further investigation is essential to substantiate these associations and evaluate the clinical value of the TyG index.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.